Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably.

PURPOSE: This phase IV trial is studying the relationship between platinum levels in the blood and neurotoxicity in patients who are receiving oxaliplatin for gastrointestinal cancer.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group; Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
• Treatments: Oxaliplatin

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of gastrointestinal cancer

• Receiving or planning to receive 8 months of oxaliplatin-based chemotherapy

• No pre-existing neuropathy

• No CNS disease or cerebral metastases

PATIENT CHARACTERISTICS:

• WHO 0-1

• Life expectancy ≥ 12 weeks

• No biliary or gastro-duodenal obstruction

• No familial, social, geographical, or psychological condition that would preclude study treatment

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No other concurrent drug or agent that is potentially neurotoxic